Immatics (IMTX) Change in Intangibles (2019 - 2025)
Immatics (IMTX) posted Change in Intangibles of -$66350.5 for Q4 2025, up 54.91% sequentially from -$147154.8 in Q2 2025, and down 3.49% YoY from -$68746.6 in Q4 2024.
Powered by 
Analysis
Immatics (IMTX) Change in Intangibles (2019 - 2025) Analysis & Trends
Immatics has reported Change in Intangibles for 7 years, with the latest figure at -$66350.5 in Q4 2025.
- Quarterly Change in Intangibles fell 3.49% year-over-year to -$66350.5 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$276618.3 (down 23.76% YoY) and the FY2025 annual result came in at -$279063.4, down 23.96% from the prior year.
- Change in Intangibles rose to -$66350.5 in Q4 2025 per IMTX's latest filing, from -$147154.8 in the prior quarter.
- Over five years, Change in Intangibles peaked at $169828.5 in Q4 2023 and troughed at -$462440.2 in Q2 2021.
- A 5-year average of -$91333.2 and a median of -$65233.1 in 2024 frame the typical range for Change in Intangibles.
- The widest YoY moves for Change in Intangibles: up 164.77% in 2023, down 3624.8% in 2023.
- Over 5 years, Change in Intangibles stood at -$73214.1 in 2021, then plunged by 258.13% to -$262203.6 in 2022, then soared by 164.77% to $169828.5 in 2023, then sank by 137.75% to -$64115.7 in 2024, then retreated by 3.49% to -$66350.5 in 2025.
- According to Business Quant data, Change in Intangibles over the past three periods registered -$66350.5, -$147154.8, and -$63113.1 for Q4 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -66,350.48 |
| Jun 30, 2025 | -147,154.76 |
| Mar 31, 2025 | -63,113.07 |
| Dec 31, 2024 | -64,115.72 |
| Jun 30, 2024 | -157,225.59 |
| Mar 31, 2024 | -2,172.72 |
| Sep 30, 2023 | -4,354.36 |
| Jun 30, 2023 | -158,982.96 |
| Mar 31, 2023 | -8,586.73 |
| Dec 31, 2022 | -262,203.57 |
| Sep 30, 2022 | -215,770.71 |
| Jun 30, 2022 | -4,268.23 |
| Mar 31, 2022 | -2,244.68 |
| Dec 31, 2021 | -73,214.14 |
| Sep 30, 2021 | -114,390.87 |
| Jun 30, 2021 | -462,440.23 |
| Mar 31, 2021 | -7,237.42 |
| Dec 31, 2020 | -21,461.22 |
| Sep 30, 2020 | -58,403.86 |
| Jun 30, 2020 | -34,145.26 |